At PhRMA, we have the honor of highlighting the hope that America’s biopharmaceutical companies bring to patients in the form of innovative treatments and cures. But beyond the value that medicines deliver to patients is the profound impact a strong biopharmaceutical sector has on our local, state and national economies.
The economic impact of the biopharmaceutical sector is detailed in a new report that was prepared for PhRMA by TEConomy Partners, LLC and which highlights how the discovery, development and delivery of innovative medicines translate into high-wage jobs, substantial tax revenue and growing economic output in our local communities.
The biopharmaceutical sector in the United States spurs economic activity and generates jobs across a whole range of sectors, from vendors and suppliers to the economic activity of its workforce. These benefits are felt far beyond individual biopharmaceutical companies. They are built upon a robust foundation of innovation-led U.S. companies that sustain a diverse and large-scale supply chain for the development, production and distribution of treatments and cures to patients.
Key findings from this examination of the broad biopharmaceutical value chain include the following:
- Nearly 4.5 million U.S. jobs. The biopharmaceutical sector’s high job multiplier— for every one job, more than four additional jobs are supported outside of the industry —translates into nearly 4.5 million jobs in the United States in 2014, including close to 854,000 direct jobs and another 3.5 million additional jobs through vendors and suppliers to the biopharmaceutical sector and businesses that serve its employees in sectors ranging from transportation and construction to health care and information technology.
- More than $1.2 trillion in economic output. The biopharmaceutical sector’s economic output, which represents the value of the goods and services produced by the sector, totaled more than $558 billion in the United States in 2014. The sector also supported another $659 billion through its vendors and suppliers and through the economic activity of its workforce, for a total of $1.2 trillion.
- Close to $311 billion paid in wages and benefits. U.S. workers in jobs supported by the biopharmaceutical sector were paid a total of nearly $311 billion in wages and benefits in 2014.
- Annual average compensation of $123,108. Employees in direct biopharmaceutical sector jobs earn an average salary of $123,108, more than twice the average $57,149 annual salary for all other U.S. jobs.
- One-third of workers in STEM occupations. One-third of the biopharmaceutical industry’s workers are in key science, technology, engineering and mathematics (STEM) occupations.
At a time when the economic competitiveness of our nation is recognized to be strongly rooted in our capacity to advance innovation-based industries, this report underscores the critical need to support policies that continue to encourage the significant research and development investments made by U.S. biopharmaceutical companies.
From the biopharmaceutical scientists working in labs to the employees on the front lines of manufacturing and distribution, each and every biopharmaceutical sector worker is instrumental in bringing new medicines to patients, strengthening the U.S. economy and maintaining our competitiveness in the global marketplace.
Priscilla VanderVeer Priscilla VanderVeer Priscilla VanderVeer is a vice president, public affairs, at PhRMA. Ms. VanderVeer has more than 15 years of experience communicating important health care issues to a wide variety of audiences, including medical, health and patient advocates; policymakers and opinion-leaders; and the general public. At PhRMA, Ms. VanderVeer leads the development and execution of communications strategies and activities for the organization’s key state advocacy priorities. She lives in Annapolis, Maryland with her husband, Ken and their two dogs: Bea Arthur, a tiny 5 lb. Maltese and Henry, a slightly larger-than-average Yorkshire Terrier.